Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 0.76 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | HTR2B | P41595 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051627 | 0.87 | HTR2B (0.59) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29424270 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL678611 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1539259 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9671595 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7056004 | 0.84 | MTNR1A (0.80) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7050446 | 0.82 | MTNR1A (0.52) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8822758 | 0.82 | MTNR1A (0.66) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17749339 | 0.82 | MTNR1A (0.65) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9671439 | 0.80 | MTNR1A (0.54) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898906-A2 | METHODS OF TREATMENT UTILIZING CERTAIN MELATONIN DERIVATIVES | Phase 2 Discovery (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2006105455-A2 | METHODS OF TREATMENT UTILIZING CERTAIN MELATONIN DERIVATIVES | PHASE 2 DISCOVERY (US) | 2006-10-05 | — | — | WO | claimed |
| US-20060223877-A1 | Methods of treatment utilizing certain melatonin derivatives | PHASE 2 DISCOVERY, INC. | 2006-10-05 | — | — | US | claimed |
| EP-0656209-B1 | Melatonin derivatives for use in treating desynchronization disorders | LILLY CO ELI (US) | 2003-05-07 | — | — | EP | claimed |
| EP-0655243-B1 | Melatonin derivatives for use in treating sleep disorders | LILLY CO ELI (US) | 2002-08-21 | — | — | EP | claimed |
| US-6180657-B1 | SLEEP DISORDERS | ELI LILLY AND COMPANY | 2001-01-30 | — | — | US | claimed |
| US-5654325-A | Melatonin derivatives for use in treating sleep disorders | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0656209-A2 | Melatonin derivatives for use in treating desynchronization disorders | ELI LILLY AND COMPANY (US) | 1995-06-07 | — | — | EP | claimed |
| EP-0655243-A2 | Melatonin derivatives for use in treating sleep disorders | ELI LILLY AND COMPANY (US) | 1995-05-31 | — | — | EP | claimed |
| JP-7196504-A | — | — | None | — | — | JP | disclosed |
| EP-1898906-A2 | METHODS OF TREATMENT UTILIZING CERTAIN MELATONIN DERIVATIVES | Phase 2 Discovery (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006105455-A2 | METHODS OF TREATMENT UTILIZING CERTAIN MELATONIN DERIVATIVES | PHASE 2 DISCOVERY (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223877-A1 | Methods of treatment utilizing certain melatonin derivatives | PHASE 2 DISCOVERY, INC. | 2006-10-05 | — | — | US | disclosed |
| EP-0656209-B1 | Melatonin derivatives for use in treating desynchronization disorders | LILLY CO ELI (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-0656209-A2 | Melatonin derivatives for use in treating desynchronization disorders | ELI LILLY AND COMPANY (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0655243-A2 | Melatonin derivatives for use in treating sleep disorders | ELI LILLY AND COMPANY (US) | 1995-05-31 | — | — | EP | disclosed |
| EP-0543659-B1 | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma | LILLY CO ELI (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0543659-A1 | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma | ELI LILLY AND COMPANY (US) | 1993-05-26 | — | — | EP | disclosed |
| US-5196435-A | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| US-4997845-A | β-alkylmelatonins as ovulation inhibitors | ELI LILLY AND COMPANY (US) | 1991-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223877-A1 | Methods of treatment utilizing certain melatonin derivatives | MTNR1A, MTNR1B, HTR6 | MTNR1A 1/4885MTNR1B 2/4885CYP1A2 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.